within Pharmacolibrary.Drugs.N_NervousSystem.N02C_AntimigrainePreparations.N02CD02_Galcanezumab;

model Galcanezumab
  extends Pharmacolibrary.Drugs.ATC.N.N02CD02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N02CD02</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Galcanezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathophysiology. It is approved for the preventive treatment of migraine in adults and also for the treatment of episodic cluster headache.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters reported for healthy subjects and patients with migraine, both sexes, adults aged 18–65 years. Values based on typical 240 mg subcutaneous loading dose followed by 120 mg monthly maintenance doses.</p><h4>References</h4><ol><li><p>Kielbasa, W, &amp; Quinlan, T (2020). Population Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine. <i>Journal of clinical pharmacology</i> 60(2) 229–239. DOI:<a href=\"https://doi.org/10.1002/jcph.1511\">10.1002/jcph.1511</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31482569/\">https://pubmed.ncbi.nlm.nih.gov/31482569</a></p></li><li><p>Monteith, D, et al., &amp; de Hoon, J (2017). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers. <i>Frontiers in pharmacology</i> 8 740–None. DOI:<a href=\"https://doi.org/10.3389/fphar.2017.00740\">10.3389/fphar.2017.00740</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29089894/\">https://pubmed.ncbi.nlm.nih.gov/29089894</a></p></li><li><p>Oakes, TMM, et al., &amp; Saper, JR (2018). Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study. <i>Cephalalgia : an international journal of headache</i> 38(6) 1015–1025. DOI:<a href=\"https://doi.org/10.1177/0333102417747230\">10.1177/0333102417747230</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29310444/\">https://pubmed.ncbi.nlm.nih.gov/29310444</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Galcanezumab;
